AN2 Therapeutics, Inc.ANTXNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank50
3Y CAGR-3.3%
5Y CAGR+39.2%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-3.3%/yr
Annual compound
5Y CAGR
+39.2%/yr
Recent deceleration
Percentile
P50
Within normal range
vs 5Y Ago
5.2x
Strong expansion
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $38.11M | -30.1% |
| 2024 | $54.55M | -21.7% |
| 2023 | $69.64M | +65.1% |
| 2022 | $42.19M | +95.5% |
| 2021 | $21.57M | +196.2% |
| 2020 | $7.28M | -76.6% |
| 2019 | $31.07M | - |